About 26S proteasome non-ATPase regulatory subunit 11
26S proteasome non-ATPase regulatory subunit 11 (PSMD11) is a protein
from Homo sapiens identified by UniProt accession
O00231, 422 residues long.
MolForge cross-references it against 0 known binders and
56 disease associations.
Target properties
| Protein name | 26S proteasome non-ATPase regulatory subunit 11 |
| UniProt accession | O00231 |
| Gene | PSMD11 |
| Organism | Homo sapiens |
| Length | 422 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (56)
Diseases linked to this target (Open Targets).
- HIV infection · score 0.46
- neurodegenerative disease · score 0.39
- Short stature · score 0.33
- breast adenocarcinoma · score 0.30
- lung adenocarcinoma · score 0.29
- endometrial cancer · score 0.29
- esophageal cancer · score 0.28
- urinary bladder cancer · score 0.28
- head and neck squamous cell carcinoma · score 0.28
- squamous cell lung carcinoma · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O00231-F1 | alphafold | PREDICTED | 82.66 | — |
Amino-acid sequence (422 residues)
MAAAAVVEFQ RAQSLLSTDR EASIDILHSI VKRDIQENDE EAVQVKEQSI LELGSLLAKT GQAAELGGLL KYVRPFLNSI SKAKAARLVR SLLDLFLDME AATGQEVELC LECIEWAKSE KRTFLRQALE ARLVSLYFDT KRYQEALHLG SQLLRELKKM DDKALLVEVQ LLESKTYHAL SNLPKARAAL TSARTTANAI YCPPKLQATL DMQSGIIHAA EEKDWKTAYS YFYEAFEGYD SIDSPKAITS LKYMLLCKIM LNTPEDVQAL VSGKLALRYA GRQTEALKCV AQASKNRSLA DFEKALTDYR AELRDDPIIS THLAKLYDNL LEQNLIRVIE PFSRVQIEHI SSLIKLSKAD VERKLSQMIL DKKFHGILDQ GEGVLIIFDE PPVDKTYEAA LETIQNMSKV VDSLYNKAKK LT
Explore 26S proteasome non-ATPase regulatory subunit 11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets